TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region of the nasal cavity, and have desirable particle size distribution, spray pattern and plume geometry A shelf-stable dry powder vaccine formulation delivered intranasally could dramatically change the existing vaccine landscape

Daniel Carlson

November 3, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

6 COMMENTS

Peter F November 7, 2022 at 6:56 am

You need to login to view this content.

Reply
- scottnice November 13, 2022 at 11:00 am
  
  You need to login to view this content.
  
  Reply
  - scottnice November 13, 2022 at 11:01 am
    
    You need to login to view this content.
    
    Reply
    - pfalker November 14, 2022 at 3:29 pm
      
      You need to login to view this content.
      
      Reply
pfalker November 3, 2022 at 3:28 pm

You need to login to view this content.

Reply
- Daniel Carlson November 4, 2022 at 3:07 pm
  
  You need to login to view this content.
  
  Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.